Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd line Hodgkin Lymphoma
16 juin 2023 07h00 HE
|
Tessa Therapeutics Ltd
Objective response observed in 9/10 patients and complete response observed in 7/10 patientsNo patients proceeded to autologous stem cell transplant (ASCT) as of data cut-off Well tolerated safety...
Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma
15 juin 2023 21h19 HE
|
Tessa Therapeutics Ltd
78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data encouraging with no graft-versus-host-disease and no...
Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano
30 mai 2023 06h12 HE
|
Tessa Therapeutics Ltd
SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute
08 mars 2023 05h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, March 08, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023
03 janv. 2023 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma
12 déc. 2022 18h50 HE
|
Tessa Therapeutics Ltd
Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 heavily pre-treated patients dosed...
Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
10 déc. 2022 14h05 HE
|
Tessa Therapeutics Ltd
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa’s “off the shelf”...
Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform
07 nov. 2022 06h00 HE
|
Tessa Therapeutics Ltd
Tessa’s TT11X utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas Exploring indications for solid tumors,...
Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition
03 nov. 2022 09h01 HE
|
Tessa Therapeutics Ltd
SINGAPORE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022
02 nov. 2022 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...